{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-080483","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2022-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.066213+00:00","generated_at":"2026-06-24T13:42:13.481122+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celldex settles Kolltan merger litigation; agrees to up to $80M in milestone payments","bullets":["Celldex pays $15M upfront; future milestones replaced with $12.5M on successful Phase II of CDX-0159 (barzolvolimab) and $52.5M on first regulatory approval.","Litigation in Delaware Court of Chancery to be dismissed with prejudice; each side bears own fees.","Prior milestone obligations under the 2016 Kolltan merger agreement are superseded; remaining payments at Celldex's election in cash or stock.","Settlement releases all claims related to the merger agreement, including those in the lawsuit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-080483","json":"https://secwatch.observer/filing/0001104659-22-080483.json","markdown":"https://secwatch.observer/filing/0001104659-22-080483.md","text":"https://secwatch.observer/filing/0001104659-22-080483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000110465922080483/0001104659-22-080483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000110465922080483/tm2221215d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T13:42:13.481122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}